RE:RE:New Press Release - Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Companylscfa wrote: Vote NO
Iscfa knows more than Ronnie Miller and Dr. Li with Gilles in the catbird seat of both companies.
The Advisory Board and Board of Directors voted
unanimously for the deal. Every one of them.
Ronnie is "thrilled" and has all the information and says that after careful consideration the merger is the best option. Derailing access to AEZS's capital could force delays unon the company, and material costs as CZO re-evaluates its options and executes on a different path. Iscfa hasn't told us how much cash CZO has left after ramping up the avenanthramide trial and simultaneously scaling PGX, etc. to 5X and 10X; including with Natex. Iscfa complained about the costs of trying to put this transaction together and may want another round of costs to try and do it with another company and he's complained about delays in the past. If shareholders won't listen to the unanimous recomendation of CZO's own Advisory Board anf Board of Directors other companies might not want the hastle of trying to merge with CZO, etc. If there are issues scaling PGX, etc., and CZO needs more capital and doesn't have the capital from this merger CZO could be compromised. Iscfa has offered no alternative financial package without warrants.
“We are thrilled with this exciting transaction to merge with Aeterna and combine two complementary companies and teams, in support of our plan to drive significant growth,” said Ronnie Miller, Chairman of Ceapro. “After careful consideration, we believe this transaction is the best way forward for Ceapro and our valued shareholders.” news release